HIV-1 replication and APOBEC3 antiviral activity are not regulated by P bodies

Journal of Virology

Volumn 86, Issue 21, 2012, Pages 11712-11724

  Phalora, Prabhjeet K ^a   Sherer, Nathan M ^a,c   Wolinsky, Steven M ^b   Swanson, Chad M ^a   Malim, Michael H ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE 3; ARGONAUTE 2 PROTEIN; CYTIDINE DEAMINASE; GAG PROTEIN; GENOMIC RNA; MESSENGER RNA; MICRORNA; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL FUNCTION; CELL ORGANELLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA PACKAGING; ENZYME ACTIVITY; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROCESSING BODY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TRANSLATION REGULATION; VIRION; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS VIRULENCE;

CELL LINE; CYTOSINE DEAMINASE; DEAD-BOX RNA HELICASES; HIV-1; HUMANS; PROTO-ONCOGENE PROTEINS; RNA STABILITY; RNA-BINDING PROTEINS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84869049177     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00595-12     Document Type: Article

References (108)

1. Adachi A, et al. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Ahluwalia JK, et al. 2008. Human cellular microRNA hsa-miR-29a interferes with viral nef protein expression and HIV-1 replication. Retrovirology 5:117. doi:10.1186/1742-4690-5-117.
3. Anant S, Davidson NO. 2000. An AU-rich sequence element (UUUN[A/U]U) downstream of the edited C in apolipoprotein B mRNA is a high-affinity binding site for Apobec-1: binding of Apobec-1to this motif in the 3' untranslated region of c-myc increases mRNA stability. Mol. Cell. Biol. 20:1982-1992.
4. Anant S, et al. 2004. Apobec-1 protects intestine from radiation injury through posttranscriptional regulation of cyclooxygenase-2 expression. Gastroenterology 127:1139-1149.
5. Arjan-Odedra S, Swanson CM, Sherer NM, Wolinsky SM, Malim MH. 2012. Endogenous MOV10 inhibits the retrotransposition of endogenous retroelements but not the replication of exogenous retroviruses. Retrovirology 9:53. doi:10.1186/1742-4690-9-53.
6. Beckham CJ, et al. 2007. Interactions between brome mosaic virus RNAs and cytoplasmic processing bodies. J. Virol. 81:9759-9768.
7. Beckham CJ, Parker R. 2008. P bodies, stress granules, and viral life cycles. Cell Host Microbe 3:206-212.
8. Beliakova-Bethell N, et al. 2006. Virus-like particles of the Ty3 retrotransposon assemble in association with P-body components. RNA 12: 94-101.
9. Berezhna SY, Supekova L, Sever MJ, Schultz PG, Deniz AA. 2011. Dual regulation of hepatitisCviralRNAby cellular RNAi requires partitioning of Ago2 to lipid droplets and P-bodies. RNA 17:1831-1845.
10. Bishop KN, Holmes RK, Malim MH. 2006. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol.80:8450-8458.
11. Bishop KN, et al. 2004. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14:1392-1396.
12. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH. 2008. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 4:e1000231. doi:10.1371/journal.ppat.1000231.
13. Bouttier M, et al. 2012. Retroviral GAG proteins recruit AGO2 on viral RNAs without affecting RNA accumulation and translation. Nucleic Acids Res. 40:775-786.
14. Burnett A, Spearman P. 2007. APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. J. Virol. 81:5000-5013.
15. Carlton JG, Agromayor M, Martin-Serrano J. 2008. Differential requirements for Alix and ESCRT-III in cytokinesis and HIV-1 release. Proc. Natl. Acad. Sci. U.S.A. 105:10541-10546.
16. Cen S, et al. 2004. The interaction between HIV-1 Gag and APOBEC3G. J. Biol. Chem. 279:33177-33184.
17. Chable-Bessia C, et al. 2009. Suppression of HIV-1 replication by microRNA effectors. Retrovirology 6:26. doi:10.1186/1742-4690-6-26.
18. Checkley MA, Nagashima K, Lockett SJ, Nyswaner KM, Garfinkel DJ.2010. P-body components are required for Ty1 retrotransposition during assembly of retrotransposition-competent virus-like particles. Mol.Cell. Biol. 30:382-398.
19. Chester A, et al. 2003. The apolipoprotein B mRNA editing complex performs a multifunctional cycle and suppresses nonsense-mediated decay. EMBO J. 22:3971-3982.
20. Chiu YL, Greene WC. 2008. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu. Rev. Immunol. 26:317-353.
21. Chiu YL, et al. 2006. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc. Natl. Acad. Sci. U.S.A. 103:15588-15593.
22. Chukkapalli V, Hogue IB, Boyko V, Hu WS, Ono A. 2008. Interaction between the human immunodeficiency virus type 1 Gag matrix domain and phosphatidylinositol-(4,5)-bisphosphate is essential for efficient gag membrane binding. J. Virol. 82:2405-2417.
23. Coller J, Parker R. 2005. General translational repression by activators of mRNA decapping. Cell 122:875-886.
24. Conticello SG, Harris RS, Neuberger MS. 2003. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13:2009-2013.
25. Cougot N, Babajko S, Seraphin B. 2004. Cytoplasmic foci are sites of mRNA decay in human cells. J. Cell Biol. 165:31-40.
26. Cullen BR. 2006. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J. Virol. 80:1067-1076.
27. Dang Y, et al. 2008. Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J. Biol. Chem. 283:11606-11614.
28. Dang Y, Wang X, Esselman WJ, Zheng YH. 2006. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 80:10522-10533.
29. Diez J, Ishikawa M, Kaido M, Ahlquist P. 2000. Identification andcharacterization of a host protein required for efficient template selection in viral RNA replication. Proc. Natl. Acad. Sci. U.S.A. 97:3913-3918.
30. Dougherty JD, White JP, Lloyd RE. 2011. Poliovirus-mediated disruption of cytoplasmic processing bodies. J. Virol. 85:64-75.
31. Dutko JA, Kenny AE, Gamache ER, Curcio MJ. 2010. 5' to 3' mRNA decay factors colocalize with Ty1 gag and human APOBEC3G and promote Ty1 retrotransposition. J. Virol. 84:5052-5066.
32. Fabian MR, Sonenberg N, Filipowicz W. 2010. Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem. 79:351-379.
33. Fisher RD, et al. 2007. Structural and biochemical studies of ALIX/AIP1 and its role in retrovirus budding. Cell 128:841-852.
34. Fouchier RA, Meyer BE, Simon JH, Fischer U, Malim MH. 1997. HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. EMBO J. 16:4531- 4539.
35. Fusco D, et al. 2003. Single mRNA molecules demonstrate probabilistic movement in living mammalian cells. Curr. Biol. 13:161-167.
36. Gallois-Montbrun S, et al. 2008. Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F andAPOBEC3Gantiviral proteins. J. Virol. 82:5636-5642.
37. Gallois-Montbrun S, et al. 2007. Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J.Virol. 81:2165-2178.
38. Goila-Gaur R, Khan MA, Miyagi E, Kao S, Strebel K. 2007. Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity. Retrovirology 4:61. doi:10.1186/1742-4690-4-61.
39. Goujon C, Malim MH. 2010. Characterization of the alpha interferoninduced postentry block to HIV-1 infection in primary human macrophages and T cells. J. Virol. 84:9254-9266.
40. Harris RS, et al. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809.
41. Hayes AM, Qian S, Yu L, Boris-Lawrie K. 2011. Tat RNA silencing suppressor activity contributes to perturbation of lymphocyte miRNA by HIV-1. Retrovirology 8:36. doi:10.1186/1742-4690-8-36.
42. Holmes RK, Koning FA, Bishop KN, Malim MH. 2007. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol.Chem. 282:2587-2595.
43. Holmes RK, Malim MH, Bishop KN. 2007. APOBEC-mediated viral restriction: not simply editing? Trends Biochem. Sci. 32:118-128.
44. Houzet L, et al. 2008. MicroRNA profile changes in human immunodeficiency virus type 1 (HIV-1) seropositive individuals. Retrovirology 5:118. doi:10.1186/1742-4690-5-118.
45. Hrecka K, et al. 2011. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474:658-661.
46. Huang M, Orenstein JM, Martin MA, Freed EO. 1995. p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J. Virol. 69:6810-6818.
47. Huang J, et al. 2007. Derepression of microRNA-mediated protein translation inhibition by apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G (APOBEC3G) and its family members. J. Biol.Chem. 282:33632-33640.
48. Huang J, et al. 2007. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+T lymphocytes. Nat. Med. 13:1241-1247.
49. Hultquist JF, et al. 2011. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85:11220-11234.
50. Huthoff H, Autore F, Gallois-Montbrun S, Fraternali F, Malim MH. 2009. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog. 5:e1000330. doi:10.1371/journal.ppat.1000330.
51. Hutvagner G, Simard MJ. 2008. Argonaute proteins: key players in RNA silencing. Nat. Rev. Mol. Cell Biol. 9:22-32.
52. Iwatani Y, et al. 2007. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 35:7096-7108.
53. Jager S, et al. 2012. Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature 481:371-375.
54. Jarmuz A, et al. 2002. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79:285-296.
55. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. 2005. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309:1577-1581.
56. Khan MA, et al. 2005. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J. Virol. 79:5870-5874.
57. Klase Z, et al. 2007. HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR. BMC Mol. Biol. 8:63.
58. Kozak SL, Marin M, Rose KM, Bystrom C, Kabat D. 2006. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J. Biol.Chem. 281:29105-29119.
59. Laguette N, et al. 2011. SAMHD1 is the dendritic- and myeloid-cellspecific HIV-1 restriction factor counteracted by Vpx. Nature 474:654-657.
60. Lecellier CH, et al. 2005. A cellular microRNA mediates antiviral defense in human cells. Science 308:557-560.
61. Liddament MT, Brown WL, Schumacher AJ, Harris RS. 2004.APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14:1385-1391.
62. Lin J, Cullen BR. 2007. Analysis of the interaction of primate retroviruses with the human RNA interference machinery. J. Virol. 81:12218-12226.
63. Liu C, et al. 2012. APOBEC3G inhibits microRNA-mediated repression of translation by interfering with the interaction between Argonaute-2 and MOV10. J. Biol. Chem. 287:29373-29383.
64. Liu J, et al. 2004. Argonaute2 is the catalytic engine of mammalian RNAi. Science 305:1437-1441.
65. Liu J, et al. 2005. A role for the P-body component GW182 in microRNA function. Nat. Cell Biol. 7:1261-1266.
66. Lu C, Contreras X, Peterlin BM. 2011. P bodies inhibit retrotransposition of endogenous intracisternal A particles. J. Virol. 85:6244-6251.
67. Lytle JR, Yario TA, Steitz JA. 2007. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR.Proc. Natl. Acad. Sci. U.S.A. 104:9667-9672.
68. Malim MH. 2009. APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos. Trans. R. Soc. Lond. B Biol. Sci. 364:675-687.
69. Mangeat B, et al. 2003. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99-103.
70. Mariani R, et al. 2003. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21-31.
71. Martin KL, Johnson M, D'Aquila RT. 2011. APOBEC3G complexes decrease human immunodeficiency virus type 1 production. J. Virol.85:9314-9326.
72. Mas A, Alves-Rodrigues I, Noueiry A, Ahlquist P, Diez J. 2006. Host deadenylation-dependent mRNA decapping factors are required for a key step in brome mosaic virus RNA replication. J. Virol. 80:246-251.
73. Mehle A, et al. 2004. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279:7792-7798.
74. Nathans R, et al. 2009. Cellular microRNA and P bodies modulate host-HIV-1 interactions. Mol. Cell 34:696-709.
75. Navarro F, et al. 2005. Complementary function of the two catalytic domains of APOBEC3G. Virology 333:374-386.
76. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430.
77. Newman EN, et al. 2005. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15:166-170.
78. Niewiadomska AM, et al. 2007. Differential inhibition of long interspersed element 1 by APOBEC3 does not correlate with high-molecularmass-complex formation or P-body association. J. Virol. 81:9577-9583.
79. Nik-Zainal S, et al. 2012. Mutational processes molding the genomes of 21 breast cancers. Cell 149:979-993.
80. Niranjanakumari S, Lasda E, Brazas R, Garcia-Blanco MA. 2002.Reversible cross-linking combined with immunoprecipitation to study RNA-protein interactions in vivo. Methods 26:182-190.
81. Noueiry AO, Diez J, Falk SP, Chen J, Ahlquist P. 2003. Yeast Lsm1p-7p/Pat1p deadenylation-dependent mRNA-decapping factors are required for brome mosaic virus genomic RNA translation. Mol. Cell. Biol.23:4094-4106.
82. OhAinle M, Kerns JA, Li MM, Malik HS, Emerman M. 2008. Antiret-roelement activity of APOBEC3H was lost twice in recent human evolution.Cell Host Microbe 4:249-259.
83. Ouellet DL, et al. 2008. Identification of functional microRNAs released through asymmetrical processing of HIV-1 TAR element. Nucleic Acids Res. 36:2353-2365.
84. Parker R, Song H. 2004. The enzymes and control of eukaryotic mRNA turnover. Nat. Struct. Mol. Biol. 11:121-127.
85. Pfeffer S, et al. 2005. Identification of microRNAs of the herpesvirus family. Nat. Methods 2:269-276.
86. Pillai RS, Artus CG, Filipowicz W. 2004. Tethering of human Ago proteins to mRNA mimics the miRNA-mediated repression of protein synthesis. RNA 10:1518-1525.
87. Reed JC, et al. 2012. HIV-1 Gag co-opts a cellular complex containing DDX6, a helicase that facilitates capsid assembly. J. Cell Biol. 198:439-456
88. Sawyer SL, Emerman M, Malik HS. 2004. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol.2:E275. doi:10.1371/journal.pbio.0020275.
89. Schafer A, Bogerd HP, Cullen BR. 2004. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 328:163-168.
90. Scheller N, et al. 2009. Translation and replication of hepatitis C virus genomic RNA depends on ancient cellular proteins that control mRNA fates. Proc. Natl. Acad. Sci. U.S.A. 106:13517-13522.
91. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
92. Sheth U, Parker R. 2003. Decapping and decay of messenger RNA occur in cytoplasmic processing bodies. Science 300:805-808.
93. Stremlau M, et al. 2004. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427:848-853.
94. Svoboda P, et al. 2004. RNAi and expression of retrotransposons MuERV-L and IAP in preimplantation mouse embryos. Dev. Biol. 269:276-285.
95. Tolia NH, Joshua-Tor L. 2007. Slicer and the Argonautes. Nat. Chem. Biol. 3:36-43.
96. Triboulet R, et al. 2007. Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science 315:1579-1582.
97. Vasudevan S, Steitz JA. 2007. AU-rich-element-mediated upregulation of translation by FXR1 and Argonaute 2. Cell 128:1105-1118.
98. Wang T, et al. 2007. 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J. Virol. 81:13112-13124.
99. Wichroski MJ, Robb GB, Rana TM. 2006. Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog. 2:e41. doi:10.1371/journal.ppat.0020041.
100. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR. 2004. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23:2451-2458.
101. Wu L, Fan J, Belasco JG. 2008. Importance of translation and nonnucleolytic ago proteins for on-target RNA interference. Curr. Biol. 18:1327-1332.
102. Yeung ML, et al. 2005. Changes in microRNA expression profiles in HIV-1-transfected human cells. Retrovirology 2:81. doi:10.1186/1742-4690-2-81.
103. Yu Q, et al. 2004. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J. Biol. Chem. 279:53379-53386.
104. Yu SF, Lujan P, Jackson DL, Emerman M, Linial ML. 2011. The DEAD-box RNA helicase DDX6 is required for efficient encapsidation of a retroviral genome. PLoS Pathog. 7:e1002303. doi:10.1371/journal.ppat.1002303.
105. Yu X, et al. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060.
106. Zennou V, Bieniasz PD. 2006. Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. Virology 349:31-40.
107. Zhang H, et al. 2003. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94-98.
108. Zhang W, Du J, Evans SL, Yu Y, Yu XF. 2012. T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481:376-379.